Blood Glucose Monitoring Device Market Report Scope & Overview:

The Blood Glucose Monitoring Device Market was valued at USD 19.07 Billion in 2025 and is expected to reach USD 40.09 Billion by 2035, growing at a CAGR of 7.71% from 2026-2035.

Blood glucose monitoring devices give people living with diabetes the ability to track their blood sugar levels, spanning the traditional fingerstick glucose meter and disposable test strip that have served as the clinical standard for decades through continuous glucose monitoring systems that use a small sensor worn on the skin to track glucose levels automatically throughout the day and night. What began as a purely reactive, episodic measurement tool has evolved into a continuously connected monitoring category, as sensor-based systems increasingly replace or supplement fingerstick testing with real-time data streams that feed directly into smartphone apps, insulin pump algorithms, and increasingly AI-powered coaching platforms. Growth is supported by the escalating global prevalence of type 1 and type 2 diabetes, growing patient awareness around the benefits of regular glucose monitoring, and continued technological innovation that keeps extending sensor wear time, improving measurement accuracy, and reducing the daily burden monitoring places on patients. Expanding insurance reimbursement for continuous glucose monitoring, reinforced by a wave of regulatory clearances making these systems available without a prescription for people without diagnosed diabetes, continues to widen the addressable market well beyond its traditional diagnosed-patient base.

⮞In April 2025, Dexcom received FDA clearance for its 15-day G7 continuous glucose monitor, extending wear time beyond the 14-day limit of rival Abbott's FreeStyle Libre 3 and giving the company a meaningful competitive edge ahead of the device's full commercial launch in the United States in December 2025, following a mean absolute relative difference accuracy measurement of 8.0% that the company positioned as among the most accurate continuous glucose monitors available.

Blood Glucose Monitoring Device Market Trends

  • Rising adoption of continuous glucose monitoring systems displacing traditional fingerstick blood glucose testing.

  • Growing availability of over-the-counter continuous glucose monitors for people without diagnosed diabetes.

  • Expanding integration of glucose data with behavioural AI coaching platforms and lifestyle tracking applications.

  • Increasing strategic collaboration between device manufacturers extending sensor compatibility across platforms.

  • Rising extended-wear sensor development reducing the frequency of device replacement for patients.

  • Growing reimbursement expansion broadening continuous glucose monitoring access beyond insulin-dependent patients.

U.S. Blood Glucose Monitoring Device Market Overview

The U.S. Blood Glucose Monitoring Device Market was valued at USD 5.87 Billion in 2025 and is expected to reach USD 11.49 Billion by 2035, growing at a CAGR of 6.95% from 2026-2035.

The U.S. Blood Glucose Monitoring Device Market benefits from a substantial and still-growing diabetic population, broad insurance and Medicare reimbursement coverage for both self-monitoring and continuous glucose monitoring devices, and the presence of leading device manufacturers headquartered in the country that continue to compete intensely on sensor accuracy, wear time, and AI-powered data integration. The competitive rivalry between leading continuous glucose monitoring manufacturers continues to drive rapid product iteration, with each new generation of sensors offering longer wear times, improved accuracy, and deeper integration with insulin delivery systems and smartphone applications than the devices they replace. A wave of regulatory clearances for over-the-counter continuous glucose monitors, available to people without a diabetes diagnosis, continues to widen the addressable market well beyond the traditional insulin-dependent patient population that has historically defined demand for these devices. Continued innovation in sensor accuracy and AI-powered coaching integration is expected to sustain strong demand growth throughout the forecast period.

⮞In August 2025, Medtronic and Abbott unveiled the Instinct sensor, a continuous glucose monitor built on Abbott's FreeStyle Libre platform and manufactured by Abbott specifically for integration with Medtronic's insulin delivery systems, reflecting what the companies describe as a landmark collaboration between two of the largest diabetes technology manufacturers in the world to expand patient access to compatible, interoperable glucose monitoring and insulin delivery technology.

Blood Glucose Monitoring Device Market Segment Analysis

  • By Device Type, the Self-Monitoring Blood Glucose Devices segment dominated the market with a 49.65% share in 2025, while the Continuous Glucose Monitoring Systems segment is the fastest growing with a CAGR of 13.45% during 2026-2035.

  • By Product, the Test Strips segment dominated the market with a 34.80% share in 2025, while the CGM Sensors segment is the fastest growing with a CAGR of 14.25% during 2026-2035.

  • By Modality, the Non-Wearable segment dominated the market with a 61.35% share in 2025, while the Wearable segment is the fastest growing with a CAGR of 13.85% during 2026-2035.

  • By Distribution Channel, the Retail Pharmacies segment dominated the market with a 44.60% share in 2025, while the Online Channels segment is the fastest growing with a CAGR of 14.65% during 2026-2035.

  • By End User, the Home Settings segment dominated the market with a 52.75% share in 2025, while the Hospitals and Clinics segment is the fastest growing with a CAGR of 9.35% during 2026-2035.

By Device Type, Self-Monitoring Blood Glucose Devices Dominates the Market and Continuous Glucose Monitoring Systems Grows Fastest

Self-monitoring blood glucose devices dominated the market in 2025. Traditional fingerstick glucose meters and test strips continue to represent the most widely used and broadly accessible glucose monitoring approach worldwide, benefiting from decades of established clinical use, favourable reimbursement and policy support in most healthcare systems, and a substantially lower per-unit cost relative to continuous glucose monitoring sensors, sustaining this device type's position as the largest category across the broader market.

Continuous glucose monitoring systems are projected to be the fastest-growing device type over the forecast period, as expanding reimbursement coverage and growing regulatory clearance for over-the-counter use continue to extend these systems well beyond their traditional insulin-dependent patient base. Continued sensor innovation, extending wear time and improving accuracy with each successive product generation, continues to drive above-market growth for this device type relative to the broader self-monitoring-dominated device type mix.

⮞In February 2026, LifeScan announced a partnership with South Korean biosensor specialist i-SENS to develop and launch a continuous glucose monitoring system under the OneTouch Vita brand, expanding LifeScan beyond traditional glucose monitoring into sensor-based monitoring technology.

By Product, Test Strips Dominates the Market and CGM Sensors Grows Fastest

Test strips dominated the market in 2025. These single-use consumables continue to generate reliable, recurring revenue tied directly to the frequency with which self-monitoring patients test their blood glucose levels throughout the day, and the sheer scale of the global self-monitoring patient population continues to anchor test strips as the largest product category across the broader blood glucose monitoring device market.

CGM sensors are projected to be the fastest-growing product category over the forecast period, registering a CAGR of 14.25%, as continued growth in continuous glucose monitoring adoption directly drives demand for the recurring sensor replacement cycle these systems require every one to two weeks depending on the specific device. Continued expansion of the continuous glucose monitoring patient population continues to drive above-market growth for this product category relative to the broader test-strip-dominated product mix.

By Modality, Non-Wearable Dominates the Market and Wearable Grows Fastest

Non-wearable devices dominated the market in 2025. Traditional handheld glucose meters, used in conjunction with disposable test strips, continue to represent the established, widely accessible approach to glucose monitoring that the overwhelming majority of the global diabetic population continues to rely on, sustaining non-wearable devices' position as the largest modality category across the broader market.

Wearable devices are projected to be the fastest-growing modality over the forecast period, as continuous and flash glucose monitoring systems, worn directly on the skin, continue to displace handheld meters among patients seeking continuous, automatic glucose tracking without the inconvenience and discomfort of repeated fingerstick testing throughout the day.

⮞In April 2026, Senseonics announced the European launch of its Eversense 365 continuous glucose monitoring system, beginning in Sweden following CE marking in January. The implantable sensor offers up to one year of use, extending the monitoring interval and reducing the frequency of sensor replacement procedures.

By Distribution Channel, Retail Pharmacies Dominates the Market and Online Channels Grows Fastest

Retail pharmacies dominated the market in 2025. These channels continue to represent the most accessible and widely used distribution point for both self-monitoring and continuous glucose monitoring devices, offering patients the convenience of in-person purchase alongside pharmacist consultation, and this established accessibility continues to anchor retail pharmacies as the leading distribution channel across the broader blood glucose monitoring device market.

Online channels are projected to be the fastest-growing distribution channel over the forecast period, as rising e-commerce pharmaceutical distribution infrastructure continues to expand patient access to both self-monitoring supplies and continuous glucose monitoring devices, particularly for stable, chronic patients who increasingly prefer home delivery of recurring consumable products over repeated pharmacy visits.

⮞In January 2026, Cardinal Health introduced ContinuCare Pathway, a pharmacy-to-supplier referral program designed to help retail pharmacies arrange direct-to-patient delivery of diabetes supplies covered under medical benefits, including continuous glucose monitors. The initiative addresses fulfillment and insurance-administration barriers in home-based diabetes care.

By End User, Home Settings Dominates the Market and Hospitals and Clinics Grows Fastest

Home settings dominated the market in 2025. The overwhelming majority of glucose monitoring, whether through self-monitoring or continuous glucose monitoring systems, continues to take place in patients' own homes as part of everyday chronic disease self-management, sustaining home settings' position as the largest end-user category across the broader blood glucose monitoring device market by a considerable margin over every clinical setting.

Hospitals and clinics are projected to be the fastest-growing end-user category over the forecast period, as rising inpatient continuous glucose monitoring adoption, particularly within intensive care and perioperative settings where precise glycaemic control genuinely improves patient outcomes, continues to expand demand for these systems beyond outpatient chronic disease management alone.

⮞In January 2026, the American Diabetes Association published its 2026 Standards of Care in Diabetes, including recommendations and guidance on glucose monitoring and the use of diabetes technology in hospital settings. The guidance reflects continued clinical attention to integrating glucose-monitoring systems into inpatient care protocols.

Regional Analysis

Region

Major Country

Share within Region, 2025

North America

United States

83.60%

Europe

Germany

26.15%

Asia Pacific

China

37.40%

Latin America

Brazil

22.60%

Middle East & Africa

United Arab Emirates

19.75%

North America Blood Glucose Monitoring Device Market Insights

North America dominated the market with a 36.85% share in 2025, anchored overwhelmingly by the United States, which alone represents a substantial majority of overall regional revenue. A substantial and growing diabetic population, broad insurance and Medicare reimbursement coverage, and the concentration of leading device manufacturers headquartered within the region continue to sustain North America's position as the clear leader across every major device type and distribution channel category.

Canada contributes meaningful incremental regional demand through its own publicly funded healthcare system, which continues to extend reimbursement coverage for continuous glucose monitoring devices. Continued competitive rivalry between leading continuous glucose monitoring manufacturers, combined with sustained AI-powered coaching platform integration, is expected to keep North America in the lead through the forecast period, even as its growth rate trails the faster-scaling markets developing across Asia Pacific.

⮞In June 2026, the U.S. Food and Drug Administration cleared Dexcom's Stelo Glucose Biosensor System for over-the-counter use in children aged two years and older who do not use insulin, extending access to glucose biosensing technology beyond the adult population previously covered by its OTC indication.

Asia Pacific Blood Glucose Monitoring Device Market Insights

Asia Pacific is projected to be the fastest-growing region over the forecast period, registering a CAGR of approximately 10.85%. A large and rapidly growing diabetic patient base in China and India, combined with urbanisation and lifestyle changes continuing to increase diabetes rates across the region's major economies, continues to accelerate regional adoption of blood glucose monitoring devices across both self-monitoring and continuous glucose monitoring categories.

China anchors regional demand through its enormous diabetic patient population and expanding domestic medical device manufacturing capability. India contributes substantial regional growth as rising urbanisation and dietary change continue to expand the diagnosed diabetic population, while Japan and South Korea add mature, technology-oriented demand through established continuous glucose monitoring adoption and reimbursement frameworks.

⮞In April 2026, China's National Medical Products Administration granted marketing authorization to InnoMind's IM-LHW-001 continuous glucose monitoring system as a Class III medical device. The system incorporates a sensor, transmitter, and monitoring application, adding a domestically developed product to China's regulated CGM market.

Europe Blood Glucose Monitoring Device Market Insights

Europe holds a significant share of the global market, anchored by Germany's substantial healthcare sector and the region's well-developed public health insurance framework, which continues to extend reimbursement coverage for continuous glucose monitoring devices to a broader share of the diagnosed diabetic population.

The United Kingdom, France, and Italy add consistent regional demand as national health systems continue extending continuous glucose monitoring access beyond insulin-dependent patients alone. Continued regional clinical guideline development supporting expanded glucose monitoring access is expected to sustain steady growth across the broader European market through the forecast period.

⮞In May 2026, Dexcom announced the launch of Dexcom Flex in Germany for adults with type 2 diabetes who do not use intensive insulin therapy. The real-time CGM system extends the company's offering to patients using basal insulin, oral antidiabetic medicines, or GLP-1 receptor agonists.

MEA and Latin America Blood Glucose Monitoring Device Market Insights

The Middle East and Africa region is supported by growing diabetes prevalence and healthcare infrastructure investment across the United Arab Emirates and Saudi Arabia, where regional governments continue expanding specialist endocrinology and diabetes care capacity as part of broader healthcare modernisation strategies.

Latin America is anchored by Brazil, where a substantial and growing diabetic population sustains steady demand for blood glucose monitoring devices. Mexico contributes further incremental growth as regional healthcare access and diabetes diagnosis rates continue to expand gradually across the broader region.

⮞In August 2026, the Saudi Food and Drug Authority authorized an innovative medical device designed to continuously monitor glucose and ketone levels using biosensor technology. The authority said the device received regulatory support through its innovative medical-device pathway, illustrating ongoing development of advanced monitoring technologies in Saudi Arabia.

Market Dynamics

Growth Drivers: Rising Diabetes Prevalence and Continuous Monitoring Innovation

The escalating global prevalence of type 1 and type 2 diabetes stands as the primary growth driver, as rising rates of obesity, sedentary lifestyles, and an ageing global population continue to expand the diagnosed diabetic patient population requiring ongoing glucose monitoring across both developed and rapidly urbanising emerging markets.

Continued technological innovation in continuous glucose monitoring represents a second major driver, as successive product generations continue to extend sensor wear time, improve measurement accuracy, and deepen integration with insulin delivery systems and smartphone applications. Growing patient awareness around the benefits of regular glucose monitoring further reinforces sustained market demand, as patients and physicians alike increasingly recognise the clinical value of continuous, real-time glucose data over episodic fingerstick measurement alone.

⮞In April 2025, the International Diabetes Federation released the 11th edition of its Diabetes Atlas, estimating that 589 million adults worldwide were living with diabetes in 2024, with 252 million unaware of their condition. The findings highlight the scale of the population requiring improved diabetes detection, management, and glucose-monitoring access.

Restraints: High Continuous Monitoring Device Cost and Reimbursement Variability

Expensive cost of CGM devices when compared to conventional self-monitoring equipment represents a real constraint as the cost difference still prevents wide use of CGM devices by patients without full insurance coverage, especially in those regions where the reimbursement policies are not fully adapted to clinical practice and evidence favoring CGMs' use.

Variations in CGM reimbursement across different health care systems and insurance programs represent another constraint as the reimbursement rates for continuous glucose monitoring vary significantly both between different countries and sometimes even between separate insurance companies in the same country.

Opportunities: Over-the-Counter Expansion and AI-Powered Coaching Integration

Continued expansion of over-the-counter continuous glucose monitoring represents a substantial opportunity, as manufacturers that can successfully extend regulatory clearance to people without diagnosed diabetes stand to capture demand from a substantially larger addressable population interested in general health and metabolic wellness monitoring beyond traditional diabetes management alone.

Continued integration of glucose data with AI-powered coaching platforms offers a further avenue for growth, as manufacturers that can deliver genuinely personalised, real-time lifestyle recommendations based on continuous glucose data are positioned to capture demand from patients and consumers increasingly interested in using glucose monitoring as a tool for broader metabolic health optimisation rather than purely reactive disease management.

⮞In August 2026, Abbott and Google Health announced a multiyear collaboration combining data from Abbott's Lingo over-the-counter continuous glucose monitor with Google Health technology. The initiative includes a large-scale research study intended to inform AI-powered coaching and future Lingo features, creating a concrete opportunity for personalized glucose insights and digital health services.

Recent Developments:

  • 2025: Dexcom received FDA clearance for integration with Signos, allowing its Stelo over-the-counter glucose biosensor to combine with behavioural AI coaching for personalised, real-time lifestyle recommendations.

  • 2025: Abbott unified its FreeStyle Libre 2 and FreeStyle Libre 3 smartphone applications into a single 'Libre by Abbott' app across the United States, streamlining the user experience across its continuous glucose monitoring product line.

Blood Glucose Monitoring Device Market Key Players are

  • Abbott Laboratories

  • Medtronic plc

  • F. Hoffmann-La Roche Ltd.

  • Dexcom, Inc.

  • Ascensia Diabetes Care Holdings AG

  • Johnson & Johnson (LifeScan)

  • Senseonics Holdings, Inc.

  • Insulet Corporation

  • Ypsomed Holding AG

  • Trividia Health, Inc.

  • ARKRAY, Inc.

  • Bionime Corporation

  • Nova Biomedical

  • i-SENS, Inc.

  • Beurer GmbH

  • B. Braun Melsungen AG

  • Terumo Corporation

  • Medtrum Technologies Inc.

  • Sinocare Inc.

  • 99 Health Ltd. (LifePlus)

Blood Glucose Monitoring Device Market Report Scope:

Report Attributes Details
Market Size in 2025 USD 19.07 Billion 
Market Size by 2035 USD 40.09 Billion 
CAGR CAGR of 7.71% From 2026 to 2035
Base Year 2025
Forecast Period 2026-2035
Historical Data 2022-2024
Report Scope & Coverage Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
Key Segments • By Device Type (Self-Monitoring Blood Glucose Devices, Continuous Glucose Monitoring Systems)
• By Product (Glucose Meters, Test Strips, Lancets, CGM Sensors, Transmitters & Receivers)
• By Modality (Wearable, Non-Wearable)
• By Distribution Channel (Retail Pharmacies, Online Channels, Hospital Pharmacies)
• By End User (Home Settings, Hospitals and Clinics, Diagnostic Centers)
Regional Analysis/Coverage North America (US, Canada), Europe (Germany, UK, France, Italy, Spain, Russia, Poland, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN Countries, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Mexico, Colombia, Rest of Latin America).
Company Profiles Abbott Laboratories, Medtronic plc, F. Hoffmann-La Roche Ltd., Dexcom, Inc., Ascensia Diabetes Care Holdings AG, Johnson & Johnson (LifeScan), Senseonics Holdings, Inc., Insulet Corporation, Ypsomed Holding AG, Trividia Health, Inc., ARKRAY, Inc., Bionime Corporation, Nova Biomedical, i-SENS, Inc., Beurer GmbH, B. Braun Melsungen AG, Terumo Corporation, Medtrum Technologies Inc., Sinocare Inc., 99 Health Ltd. (LifePlus)